Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05337891
Other study ID # JagiellonianU70
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date June 3, 2022
Est. completion date September 1, 2024

Study information

Verified date September 2023
Source Jagiellonian University
Contact Jakub M Antczak, MD
Phone +48 795 421 153
Email jantczak@cm-uj.krakow.pl
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Myasthenia gravis (MG) is the autoimmune disorder affecting the neuromuscular junction, characterized by fatigue, which increases gradually through the day. The repetitive nerve stimulation (RNS) remains the key diagnostic test in MG, however its sensitivity, especially in ocular form of MG is not satisfactory. In this study, investigators want to assess the impact of the time of the day on the sensitivity of the RNS. We hypothesize the RNS performed in the evening may be more sensitive than in the morning.


Description:

Myasthenia gravis (MG) is the autoimmune disorder affecting the neuromuscular junction with morbidity estimated at 70-320 per 1 000 000. The main symptom is the fatigue, which increases gradually through the day and also after exercise. The repetitive nerve stimulation (RNS) remains the key diagnostic test. In RNS, the peripheral nerve is electrically stimulated with trains of repetitive pulses at constant (e.g. 3Hz) frequency. The electrical responses associated with contraction of the one of respectively innervated muscles are recorded. While in healthy subject the amplitudes of subsequent responses should be similar, in MG they gradually decrease reflecting the insufficiency of neuromuscular junction and being the electrophysiological correlate of the fatigue. RNS is relatively simple, safe as well as time and cost-effective procedure. However, its sensitivity is not satisfactory. Even when voluntary exercise and other provocative methods are implemented, the sensitivity does not exceed 89% in generalized form of MG (where symptoms affect bulbar, limb and other muscles) and 70% in ocular form (where symptoms are limited to bulbar muscles). In some laboratories the sensitivity of detecting the impaired neuromuscular transmission can be increased with the use of the single fiber electromyography. This method is however not widely available as it requires skilled personnel and dedicated software. It is also not specific for MG. Therefore, research effort is still being done to increase the sensitivity of the RNS. The well-known gradual exacerbation of MG-related fatigue through the day let us to hypothesize, the RNS performed in the evening may be more sensitive than in the morning. The primary objective of this study will be therefore a comparison of RNS sensitivity performed in these both times of the day. Additionally, investigators want to assess if adding the second voluntary effort could be another way of improving the RNS-sensitivity. The maximal voluntary effort of the investigated muscle, lasting between 30 seconds and one minute is typically done in the course of the RNS. Usually, one or several trains of five to ten impulses precede it and also several trains follow it. While prolonging the effort over one minute may cause discomfort or problems with adherence, adding second one-minute effort, separated from the first by several trains should be suitable and well tolerable. It will prolong the whole procedure by approximately six minutes minutes. Diagnostic procedure: In every recruited patient, RNS will be done thrice at 8:30 a.m., 8:50 a.m. and 2:30 p.m. on the same day or at 8:30 a.m. and 8:50 a.m. on one day and at 2:30 p.m. on the subsequent day. To exclude peripheral neuropathy, before the first RNS, the sensory nerve conduction study will be performed on the sural nerve and the motor conduction study on the tibial nerve on the nondominant side. To exclude myopathy, before the first RNS, the needle electromyography will be performed on the biceps brachii, of dominant side. Also, before the first RNS, the Myasthenia Gravis - Activities of Daily Living Score (MG-ADL) will be filled out. Every RNS will comprise investigation of the nasalis and trapezius muscles on the clinically more affected side or on the nondominant side when lateralization will not be evident. Investigation of every muscle will include two, 3Hz trains of ten supramaximal electric stimuli, separated by 1 minute interval. Then the 1 minute of maximal voluntary effort will follow and after that six 3Hz trains of ten supramaximal stimuli, separated by 1-minute intervals. The first or the second RNS (at 8:30 or at 8:50 a.m.) will include additional 1 minute of maximal voluntary effort, followed by additional six 3Hz trains of ten supramaximal stimuli, separated by 1-minute intervals. The allocation of the additional voluntary effort and subsequent six trains to the first or to the second RNS will be done randomly. The randomization list will be created via the website www.randomization.com using blocks of five subjects. The amplitude drop (the decrement) of the fourth response (out of 10 in every train) >=10% with respect to the first response will be considered abnormal (indicative of impaired neuromuscular transmission). The whole RNS will be considered abnormal (indicative of impaired neuromuscular transmission) when the decrement >=10% will be repeatable in at least several trains in at least one out of two tested muscles. The temperature of the skin will be maintained at 35 Celsius. If being taken, the acetylcholinesterase inhibitors will be withheld 12 hours before the first RNS.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date September 1, 2024
Est. primary completion date May 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Patients with suspected or diagnosed myasthenia gravis (ocular and generalized form) - Patients with performed or planned determination of anti-AChrR and anti-MUSK antibodies. - Disease severity of at least 1 in the classification of the severity of myasthenia gravis according to the recommendations of the Myasthenia Gravis Foundation of America Exclusion Criteria: - respiratory failure - severe bulbar symptoms - pharmacotherapy with substances that may worsen neuromuscular transmission disorders - current infection - coexisting diseases of the peripheral nervous system which may affect the result of the fatigue test, e.g. polyneuropathy or myopathy - cognitive and behavioral disorders that may negatively affect patient's adherence to study protocol - Medication with steroids due to myasthenia - Severity of myasthenia that makes the discontinuation of acetylcholinesterase inhibitors unsafe.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Poland Jagiellonian University Medical College, Department of Neurology Kraków Lesser Poland

Sponsors (1)

Lead Sponsor Collaborator
Jagiellonian University

Country where clinical trial is conducted

Poland, 

References & Publications (4)

Bou Ali H, Salort-Campana E, Grapperon AM, Gallard J, Franques J, Sevy A, Delmont E, Verschueren A, Pouget J, Attarian S. New strategy for improving the diagnostic sensitivity of repetitive nerve stimulation in myasthenia gravis. Muscle Nerve. 2017 Apr;55 — View Citation

Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Ne — View Citation

Witoonpanich R, Dejthevaporn C, Sriphrapradang A, Pulkes T. Electrophysiological and immunological study in myasthenia gravis: diagnostic sensitivity and correlation. Clin Neurophysiol. 2011 Sep;122(9):1873-7. doi: 10.1016/j.clinph.2011.02.026. Epub 2011 — View Citation

Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ. Myasthenia gravis activities of daily living profile. Neurology. 1999 Apr 22;52(7):1487-9. doi: 10.1212/wnl.52.7.1487. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Difference in the highest decrement between investigation of nasalis during morning and evening RNS Difference in the highest decrement between investigation of nasalis during morning (at 8:30 or 8:50 a.m.) RNS with single one-minute voluntary effort and RNS at 2:30 p.m. Through study completion, an average of 1 year.
Primary Difference in the highest decrement between investigation of trapezius during morning and evening RNS Difference in the highest decrement between investigation of trapezius during morning (at 8:30 or 8:50 a.m.) RNS with single one-minute voluntary effort and RNS at 2:30 p.m. Through study completion, an average of 1 year.
Primary Difference in the highest decrement between investigation of nasalis during morning RNS with single and with two voluntary efforts Difference in the highest decrement between investigation of nasalis during morning (at 8:30 or 8:50 a.m.) RNS with single one-minute voluntary effort and RNS with two one-minute voluntary efforts. Through study completion, an average of 1 year.
Primary Difference in the highest decrement between investigation of trapezius during morning RNS with single and with two voluntary efforts Difference in the highest decrement between investigation of trapezius during morning (at 8:30 or 8:50 a.m.) RNS with single one-minute voluntary effort and RNS with two one-minute voluntary efforts. Through study completion, an average of 1 year.
Secondary Difference in the percentage of abnormal RNS results between RNS performed in the morning and in the evening Difference in the percentage of abnormal RNS results between RNS with single one-minute voluntary effort performed in the morning (at 8:30 or 8:50 a.m.) and RNS performed at 2:30 p.m. Through study completion, an average of 1 year.
Secondary Difference in the percentage of abnormal RNS results between RNS performed in the morning with single and with two voluntary efforts Difference in the percentage of abnormal RNS results between RNS with single one-minute voluntary effort performed at 8:30 or 8:50 a.m. and RNS with two one-minute voluntary efforts. Through study completion, an average of 1 year.
Secondary Correlation between the highest decrement during morning RNS with single one-minute voluntary effort and the MG-ADL score Correlation between the highest decrement during RNS with single one-minute voluntary effort, performed at 8:30 or 8:50 AM and the MG-ADL score Through study completion, an average of 1 year.
Secondary Correlation between the highest decrement during RNS with two one-minute voluntary efforts and the MG-ADL score Correlation between the highest decrement during RNS with two one-minute voluntary efforts, and the MG-ADL score Through study completion, an average of 1 year.
Secondary Correlation between the highest decrement during evening RNS and the MG-ADL score Correlation between the highest decrement during RNS performed at 2:30 p.m. and the MG-ADL score Through study completion, an average of 1 year.
See also
  Status Clinical Trial Phase
Completed NCT05039190 - Evaluate the Efficacy and Safety of HBM9161(HL161)Subcutaneous Injection in Patients With Generalized MG Patients Phase 3
Recruiting NCT04561557 - Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System Early Phase 1
Completed NCT01727193 - The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand Thymectomy Phase 3
Completed NCT00285350 - Mycophenolate Mofetil in Myasthenia Gravis Phase 3
Recruiting NCT05890833 - The Risk of Falls Index for Patients With Neuromuscular Disorders
Completed NCT05694234 - Influences of Sugammadex on Postoperative Progress in Patients With Myasthenia Gravis Undergoing Video-assisted Thoracoscopic Thymectomy: Retrospective Study
Recruiting NCT05635266 - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Not yet recruiting NCT05095103 - Immune Profiles in Myasthenia Gravis
Not yet recruiting NCT04965987 - Oxaloacetate in Myasthenia Gravis Phase 1
Terminated NCT02102594 - Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB) Phase 2
Completed NCT02774239 - A Pilot Trial To Assess The Feasibility And Efficacy Of SCIG In Patients With MG Exacerbation (SCIG-MG) Phase 3
Completed NCT02066519 - Benefits and Tolerance of Exercise in Patients With Generalized and Stabilized Myasthenia Gravis N/A
Completed NCT02118805 - Innovative Measures of Speech and Swallowing Dysfunction in Neurological Disorders
Terminated NCT01828294 - Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis Phase 1
Terminated NCT00727194 - Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis Phase 2
Completed NCT04590716 - Help Build an A.I. Model to Predict Myasthenia Gravis Symptom Patterns and Flares
Recruiting NCT04837625 - Study of Myasthenic Crisis in China
Not yet recruiting NCT01469858 - Perception and Multisensory Integration in Neurological Patients Using fMRI N/A
Completed NCT05408702 - Exercise in Autoimmune Myasthenia Gravis and Myasthenic Syndromes
Completed NCT03205306 - Myasthenia Gravis and Psyche